22 jun: Belgium June Business Confidence -13.2 Vs -11.2 In May
22 jun: Brazil Government Will Cut Fuel Tax To Help Petrobras -Report
22-06-2012 15:35:00

EMA Recommends Against Marketing Authorization to Pfizer and Protalix for Gaucher Treatment

Relateret indhold
Relateret debat
16 jul - 
Interesting case study. There are a few key points I di..
11 jul - 
Right keywords will help the video display in appropria..
24 jun - 
A multimedia company that provides a combined solution ..

By Saabira Chaudhuri

The European Medicines Agency has recommended against marketing authorization for Pfizer Inc. (PFE) and Protalix BioTherapeutics Inc. (PLX) for their Gaucher disease treatment, taliglucerase alfa.

Protalix's shares were down 12% premarket to $5.83. The stock is up 34% year-to-date. Pfizer's shares were flat premarket at $22.60. The stock is up 4% year-to-date.

The European agency made a positive risk-benefit assessment, concluding that the benefits of the treatment outweighed its risks, but didn't recommend marketing authorization because Shire PLC's (SHPGY, SHP.LN) velaglucerase alfa has received prior marketing authorization with an orphan drug designation for the same condition. Shire's treatment has marketing exclusivity in the European Union for 10 years from August 2010, the time of authorization.

"While we are disappointed by the CHMP's [EMA's Committee for Medicinal Products for Human Use] recommendation, we are encouraged that the committee gave a positive risk-benefit assessment. The recommendation was based solely on orphan market exclusivity and not the safety and efficacy profile of taliglucerase alfa," said General Manager Diem Nguyen of Pfizer's Biosimilars division. "Pfizer will continue to work with relevant stakeholders to determine appropriate next steps."

Pfizer and Protalix BioTherapeutics entered into an agreement to develop and commercialize taliglucerase alfa, an enzyme replacement therapy, in November 2009. The treatment was approved by the Food and Drug Administration last month for the long term enzyme replacement therapy of adults with a confirmed diagnosis of Type 1 Gaucher disease.

According to the National Institute of Health's National Institute of Neurological Disorders and Stroke, Gaucher disease is the most common of the inherited metabolic disorder known as lipid storage diseases. Lipids are fatty materials that include oils, fatty acids, waxes, and steroids [such as cholesterol and estrogen]. Gaucher disease is caused by a deficiency of the enzyme glucocerebrosidase. Fatty materials can accumulate in the spleen, liver, lungs, bone marrow, and brain. Symptoms may include skeletal disorders, enlarged spleen and liver, liver malfunction, anemia, and yellow spots in the eyes.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

(END) Dow Jones Newswires

June 22, 2012 09:35 ET (13:35 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Branchegruppe tror på mindre vind i Europa

23-07-2014 15:11:15
Den europæiske vindmøllebranches fællesorganisationen, EWEA, skruer i en ny rapport ned for fremtidsudsigterne for mængden af nye vindmøller i verdensdelen.I en..

Nordea i russisk offensiv - netmedie

23-07-2014 12:15:50
Selvom Ukraine-krisen, der begyndte i februar-marts har medført, at udenlandske banker har trukket sig fra det russiske lånemarked, er det ikke tilfældet for No..

Aktier/åbning: Investorer børster ja-hatten af fra start

23-07-2014 09:24:32
Trods udsigt til fald i futuremarkedet og et totalt fravær af nævneværdige nøgletal har investorerne fundet det gode humør frem onsdag morgen. Dermed stiger de ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Pandora/JPMorgan: Kursmål hævet til 490 kr.
2
Onsdagens aktier: Bunden gik ud af GN og Pandora
3
Aktier/tendens: Let negativ start i kortene
4
Finanstilsynet hæver værdien af landbrugsjord - avis
5
Nordea i russisk offensiv - netmedie

Relaterede aktiekurser

Pfizer Inc 30,39 -0,3% Fald i aktiekurs
Shire ORD 5P 4.977,00 0,0% Aktiekurs uændret
Pfizer 27,10 0,0% Aktiekurs uændret
Pfizer Incorporated COM .. 30,26 0,0% Aktiekurs uændret
Pfizer Inc 206,50 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen
Køb

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. juli 2014 06:22:09
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140723.1 - EUROWEB3 - 2014-07-24 06:22:09 - 2014-07-24 06:22:09 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x